title: The ARMYDA trials (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) at Campus Bio-Medico University: rationale, results and future horizons.
abstract: Myocardial protection by atorvastation pretreatment was found in several trials applied to percutaneous coronary intervention by the ARMYDA study group. This article reviews those studies and explores future avenues.
authors.affiliation: Department of Cardiovascular Sciences, Campus Bio-Medico, University of Rome, Rome, Italy.
authors.forename: Germano
authors.initials: G
authors.lastname: di Sciascio
mesh_terms: D000787:Angina Pectoris / Q000601:surgery; D017130:Angioplasty / Q000009:adverse effects*; D000069059:Atorvastatin; D009202:Cardiomyopathies / Q000209:etiology / Q000517:prevention & control*; D005544:Forecasting; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000639:trends; D016896:Treatment Outcome
chemical_list: D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin